Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and Eli Lilly and Company have expanded their collaboration in cancer immunotherapy to test new drug combinations for treating solid tumours.
Subscribe to our email newsletter
The expanded deal will see both the companies evaluate the safety and efficacy of a range of additional combinations across their portfolios.
Lilly will lead the studies, while both firms will contribute resources. The companies did not disclose the details of financial arrangements and tumours to be studied.
AstraZeneca’s anti-PD-L1 medicine durvalumab will be combined with Lilly molecules, including a TGF-beta kinase inhibitor, a CXCR4 peptide antagonist and an anti-CSF-1R monoclonal antibody.
The CSF-1R antibody will also be assessed with AstraZeneca’s tremelimumab. The companies will also explore other combinations targeting tumour drivers and resistance mechanisms.
Lilly Oncology senior vice president, product development and medical affairs Richard Gaynor said: "The expansion of Lilly’s research partnership with AstraZeneca will explore the far-reaching potential of combining novel targeted therapies.
"Our respective pipelines afford multiple targeted options to create innovative combinations in immuno-oncology and beyond, that we hope will lead to future cancer treatment options."
Earlier this year, AstraZeneca and Lilly unveiled a Phase I clinical trial collaboration to evaluate the safety and preliminary efficacy of combining durvalumab and ramucirumab to treat patients with advanced solid tumours.